机译:Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment
Pfizer Inc., La Jolla;
Pfizer Ltd.;
Investigational Cancer Therapeutics,The University of Texas MD Anderson Cancer CenterOrlando Health Inc.Pfizer Inc.University of California Los Angeles David Geffen School of Medicine;
hepatic impairment; pharmacokinetics; phase I; PK modelling; talazoparib;